Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment

被引:36
作者
Sidhu, Mandeep S. [1 ,2 ]
Desai, Karan P. [2 ]
Lynch, Heather N. [3 ]
Rhomberg, Lorenz R. [3 ]
Beck, Barbara D. [3 ]
Venditti, Ferdinand J. [1 ,2 ]
机构
[1] Albany Med Ctr, Dept Med, Div Cardiol, Albany, NY 12208 USA
[2] Albany Med Coll, Albany, NY USA
[3] Gradient, Cambridge, MA USA
关键词
Arsenic; Atherosclerosis; Cardiovascular disease; Cardiovascular toxicity; Mechanism of action; DOSE-RESPONSE RELATIONSHIP; HIGH-DENSITY-LIPOPROTEIN; INDUCED OXIDATIVE STRESS; FATTY LIVER-DISEASE; DRINKING-WATER; GENE-EXPRESSION; DIABETES-MELLITUS; REACTIVE OXYGEN; DOUBLE-BLIND; ANTIOXIDANT SUPPLEMENTATION;
D O I
10.1016/j.tox.2015.02.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The possibility of an association between inorganic arsenic (iAs) exposure and cardiovascular outcomes has received increasing attention in the literature over the past decade. The United States Environmental Protection Agency (US EPA) is currently revising its Integrated Risk Assessment System (IRIS) review of iAs, and one of the non-cancer endpoints of interest is cardiovascular disease (CVD). Despite the increased interest in this area, substantial gaps remain in the available information, particularly regarding the mechanism of action (MOA) by which iAs could cause or exacerbate CVD. Few studies specifically address the plausibility of an association between iAs and CVD at the low exposure levels which are typical in the United States (i.e., below 100 mu g As/L in drinking water). We have conducted a review and evaluation of the animal, mechanistic, and human data relevant to the potential MOAs of iAs and CVD. Specifically, we evaluated the most common proposed MOAs, which include disturbance of endothelial function and hepatic dysfunction. Our analysis of the available evidence indicates that there is not a well-established MOA for iAs in the development or progression of CVD. Few human studies of the potential MOAs have addressed plausibility at low doses and the applicability of extrapolation from animal studies to humans is questionable. However, the available evidence indicates that regardless of the specific MOA, the effects of iAs on physiological processes at the cellular level appear to operate via a threshold mechanism. This finding is consistent with the lack of association of CVD with iAs exposure in humans at levels below 100 mu g/L, particularly when considering important exposure and risk modifiers such as nutrition and genetics. Based on this analysis, we conclude that there are no data supporting a linear dose-response relationship between iAs and CVD, indicating this relationship has a threshold. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:78 / 99
页数:22
相关论文
共 171 条
  • [1] Overproduction of large VLDL particles is driven by increased liver fat content in man
    Adiels, M
    Taskinen, MR
    Packard, C
    Caslake, MJ
    Soro-Paavonen, A
    Westerbacka, J
    Vehkavaara, S
    Hakkinen, A
    Olofsson, SO
    Yki-Jarvinen, H
    Borén, J
    [J]. DIABETOLOGIA, 2006, 49 (04) : 755 - 765
  • [2] Agency for Toxic Substances and Disease Registry (ATSDR), 2007, DRAFT FOR PUBLIC COM
  • [3] Heavy Metal Poisoning and Cardiovascular Disease
    Alissa, Eman M.
    Ferns, Gordon A.
    [J]. JOURNAL OF TOXICOLOGY, 2011, 2011
  • [4] AS3MT, GSTO, and PNP polymorphisms: Impact on arsenic methylation and implications for disease susceptibility
    Antonelli, Ray
    Shao, Kan
    Thomas, David J.
    Sams, Reeder, II
    Cowden, John
    [J]. ENVIRONMENTAL RESEARCH, 2014, 132 : 156 - 167
  • [5] Lipoprotein(a): A unique risk factor for cardiovascular disease
    Anuurad, Erdembileg
    Boffa, Michael B.
    Koschinsky, Marlys L.
    Berglund, Lars
    [J]. CLINICS IN LABORATORY MEDICINE, 2006, 26 (04) : 751 - +
  • [6] A review of the enzymology of arsenic metabolism and a new potential role of hydrogen peroxide in the detoxication of the trivalent arsenic species
    Aposhian, HV
    Zakharyan, RA
    Avram, MD
    Sampayo-Reyes, A
    Wollenberg, ML
    [J]. TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 198 (03) : 327 - 335
  • [7] Arias I M, 1990, Prog Liver Dis, V9, P11
  • [8] Evaluation of urinary speciated arsenic in NHANES: Issues in interpretation in the context of potential inorganic arsenic exposure
    Aylward, Lesa L.
    Ramasamy, Santhini
    Hays, Sean M.
    Schoeny, Rita
    Kirman, Christopher R.
    [J]. REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2014, 69 (01) : 49 - 54
  • [9] Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
    Back, Magnus
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (27) : 3116 - 3132
  • [10] Arsenic Exposure and Cardiovascular Disorders: An Overview
    Balakumar, Pitchai
    Kaur, Jagdeep
    [J]. CARDIOVASCULAR TOXICOLOGY, 2009, 9 (04) : 169 - 176